Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BAYOU trial: what clinicians have said so far
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
- NCT03459846 ↗
- Active, not recruiting
- AstraZeneca
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on BAYOU (previously untreated, platinum-ineligible metastatic urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BAYOU so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Durvalumab; Olaparib; Placebo
- Arms
- Arm 1: Durvalumab/Placebo · Experimental
- Arm 2: Durvalumab/Olaparib · Experimental
- Enrollment
- 154
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- AstraZeneca
- Start
- Mar 16, 2018
- Primary completion
- Oct 15, 2020
- Results posted
- Yes
- Registry record
- NCT03459846 · updated Aug 5, 2026
Publications
linked from the registry- Rosenberg JE, Park SH, Kozlov V, Dao TV, Castellano D, Li JR, Mukherjee SD, Howells K, Dry H, Lanasa MC, Stewart R, Bajorin DF. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). J Clin Oncol. 2023 Jan 1;41(1):43-53. doi: 10.1200/JCO.22.00205. Epub 2022 Jun 23. PubMed 35737919